| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$188 |
ACW achieves early screening closure for XanaMIA trial
|
20 Oct 2025 9:04AM |
$0.030 |
$0.059 |
risen by
96.67%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- pTau biomarker screening closes early on October 31, 2025.
- Projected total enrolment increased to approximately 240 participants.
- Currently 180 participants are enrolled.
- The trial is being conducted in Australia and the U.S.
- Primary endpoint is the Clinical Dementia Rating scale – Sum of Boxes (CDR-SB).
- Projected topline final results expected mid Q4 2026.
- Xanamem showed benefits on depressive symptoms in previous trials.
- A formal interim analysis of safety and efficacy futility will occur in January 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sarytogan Graphite Limited (SGA) ORDINARY FULLY PAID |
Materials |
$20 |
IMARC Investor Conference Presentation
|
20 Oct 2025 9:04AM |
$0.155 |
$0.098 |
fallen by
36.77%
|
|
| Kalamazoo Resources Limited (KZR) ORDINARY FULLY PAID |
Materials |
$47 |
Significant Update - Gold Resource & Exploration Target
|
20 Oct 2025 9:03AM |
$0.205 |
$0.195 |
fallen by
4.88%
|
|
KZR - Price-sensitive ASX Announcement
Full Release
Key Points
- Re-optimisation of Mt Olympus underground resource to 1.44 Mt at 3.76 g/t Au for 174,500 ounces.
- Underground Exploration Target of 2.0 - 6.0 Mt at 2 g/t Au for 129,000 – 387,000 ounces.
- Drilling program designed to convert Inferred material to Indicated category.
- Scoping Study due in Q4 2025.
- Pre-Feasibility Study planned based on positive outcomes.
- Focus on extending multi-year gold production at Ashburton Gold Project.
- Further exploration planned at Peake, Zeus, and other Ashburton-Xanadu Gold Project prospects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Beach Energy Limited (BPT) ORDINARY FULLY PAID |
Energy |
$2,612 |
FY26 First Quarter Activities Report
|
20 Oct 2025 9:03AM |
$1.090 |
$1.145 |
risen by
5.05%
|
|
BPT - Price-sensitive ASX Announcement
Full Release
Key Points
- Production increased by 8% quarter-on-quarter to 5.0 MMboe.
- Sales volumes up 15% to 6.8 MMboe and sales revenue up 18% to $537 million.
- Two Waitsia LNG cargoes lifted, contributing $121 million in revenue.
- Cooper Basin JV production increased by 10% due to flood recovery efforts.
- Waitsia Gas Plant approaching Ready For Start Up milestone.
- Flood recovery activities in Cooper Basin to continue into Q2 FY26.
- Successful plug and abandonment of wells in the Otway Basin.
- Strong liquidity position with $586 million despite refinance and capital expenditures.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lincoln Minerals Limited (LML) ORDINARY FULLY PAID |
Materials |
$34 |
Final Director's Interest Notice JB
|
20 Oct 2025 9:02AM |
$0.008 |
$0.013 |
risen by
62.50%
|
|
| ClearVue Technologies Limited (CPV) ORDINARY FULLY PAID |
Industrials |
$41 |
Update - Accelerating ClearVue Global Commercialisation
|
20 Oct 2025 9:02AM |
$0.205 |
$0.135 |
fallen by
34.15%
|
|
| Evion Group NL (EVG) ORDINARY FULLY PAID |
Materials |
$17 |
International support for new government in Madagascar
|
20 Oct 2025 9:02AM |
$0.022 |
$0.030 |
risen by
36.36%
|
|
| Locksley Resources Limited (LKY) ORDINARY FULLY PAID |
Materials |
$71 |
Locksley Delivers 100% American Made Antimony Ingot
|
20 Oct 2025 9:02AM |
$0.490 |
$0.200 |
fallen by
59.18%
|
|
LKY - Price-sensitive ASX Announcement
Full Release
Key Points
- Locksley produced 100% American-made antimony ingot from Mojave.
- Achievement validates a U.S mine-to-metal supply chain for antimony.
- Supports U.S Government initiatives for critical minerals security.
- Locksley advancing pilot-scale production for scalability and commercial supply.
- Pilot production targets U.S defense and industrial sectors.
- Locksley collaborates with Washington D.C based advisors GreenMet.
- Focus on scaling and refining processes for larger scale operations.
- Engagement with U.S. government for offtake qualification and strategic collaboration.
- Locksley's success aligns with U.S. objectives and reduces dependency on Chinese supply chains.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lithium Plus Minerals Ltd (LPM) ORDINARY FULLY PAID |
Materials |
$23 |
Mining Lease granted for Lei Lithium Project
|
20 Oct 2025 9:01AM |
$0.155 |
$0.175 |
risen by
12.90%
|
|
| Rimfire Pacific Mining Limited (RIM) ORDINARY FULLY PAID |
Materials |
$40 |
Currajong MRE increases Rimfire Sc resources by 61%
|
20 Oct 2025 9:01AM |
$0.017 |
$0.015 |
fallen by
14.71%
|
|
RIM - Price-sensitive ASX Announcement
Full Release
Key Points
- Maiden scandium Mineral Resource at Currajong increases Rimfire's resources by 61%.
- Currajong adds 2,059 tonnes of scandium to inventory.
- Rimfire's total scandium inventory now stands at 5,449 tonnes.
- Further exploration recommended to expand Currajong resources.
- Additional potential at Murga and Rabbit Trap projects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Credit Clear Limited (CCR) ORDINARY FULLY PAID |
Information Technology |
$124 |
Trading halt
|
20 Oct 2025 9:01AM |
$0.270 |
$0.260 |
fallen by
3.70%
|
|
CCR - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt requested by Credit Clear Limited (ASX: CCR).
- Purpose is to manage continuous disclosure obligations.
- Pending announcement related to corporate transaction and capital raise.
- Trading halt effective until October 22, 2025, or earlier announcement.
- Request made in accordance with ASX Listing Rule 17.1.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Apiam Animal Health Limited (AHX) ORDINARY FULLY PAID |
Health Care |
$161 |
Notification of cessation of securities - AHX
|
20 Oct 2025 9:01AM |
$0.810 |
$0.870 |
risen by
7.41%
|
|
| Regal Investment Fund (RF1) ORDINARY UNITS FULLY PAID |
Financials |
$738 |
Update - Notification of buy-back - RF1
|
20 Oct 2025 8:59AM |
$3.340 |
$3.500 |
risen by
4.79%
|
|
| Algorae Pharmaceuticals Limited (1AI) ORDINARY FULLY PAID |
Health Care |
$24 |
Algorae Signs Binding Term Sheet with Cadila Pharmaceuticals
|
20 Oct 2025 8:59AM |
$0.011 |
$0.014 |
risen by
27.27%
|
|
1AI - Price-sensitive ASX Announcement
Full Release
Key Points
- Algorae Pharmaceuticals partners with Cadila Pharmaceuticals for Australian and New Zealand markets.
- The partnership aims to launch two generic medicines for cardiovascular and metabolic disorders.
- A definitive License and Supply Agreement will be established.
- Algorae will initiate TGA registration for product commercialization.
- Cadila Pharmaceuticals is a globally recognized Indian pharmaceutical company.
- The partnership is a step in Algorae's commercial strategy and portfolio expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Racura Oncology Ltd (RAC) ORDINARY FULLY PAID |
Health Care |
$488 |
Race Presents Mechanism of Action Data at ESMO 2025
|
20 Oct 2025 8:58AM |
$4.250 |
$2.700 |
fallen by
36.47%
|
|
RAC - Price-sensitive ASX Announcement
Full Release
Key Points
- Race Oncology presented data at ESMO 2025 on (E,E)-bisantrene's dual anticancer and cardioprotective effects when combined with doxorubicin.
- The combination of (E,E)-bisantrene and doxorubicin demonstrated enhanced anticancer activity and cardioprotection by reducing DNA damage in heart cells.
- The current Phase 1 trial of RC220 is evaluating this combination in patients with advanced solid tumors.
- Race Oncology aims to address high unmet needs in oncology with the RC220 formulation, focusing on combinations with anthracyclines.
- The company is exploring partnerships and licensing opportunities to accelerate access to RC220 globally.
- (E,E)-bisantrene acts by stabilizing G4-DNA and RNA structures, leading to the silencing of the MYC oncogene.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Imricor Medical Systems Inc (IMR) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$469 |
Imricor Performs World's First PFA Ablation in the iCMR
|
20 Oct 2025 8:57AM |
$1.500 |
$1.460 |
fallen by
2.67%
|
|
IMR - Price-sensitive ASX Announcement
Full Release
Key Points
- Imricor performed the world's first in vivo PFA ablation under real-time MRI guidance.
- The procedure was conducted in an iCMR lab using the Vision-MR Ablation Catheter.
- This achievement is a significant step in Imricor's PFA development program.
- PFA is emerging as a promising energy source for treating atrial fibrillation.
- Imricor aims to enable MRI-guided procedures regardless of energy source.
- The company is a pioneer in developing MRI-compatible cardiac catheter ablation products.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Westar Resources Limited (WSR) ORDINARY FULLY PAID |
Materials |
$3 |
Trading Halt
|
20 Oct 2025 8:57AM |
$0.009 |
$0.006 |
fallen by
33.33%
|
|
WSR - Price-sensitive ASX Announcement
Full Release
Key Points
- Westar Resources Limited (ASX: WSR) requested a trading halt.
- The trading halt is pending a material capital raising announcement.
- The halt will be lifted on 22 October 2025 or upon the announcement's release.
- The trading halt request complies with ASX Listing Rule 17.1.
- Westar Resources Limited operates in Perth and focuses on gold and copper projects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Orthocell Limited (OCC) ORDINARY FULLY PAID |
Health Care |
$290 |
OCC Secures Rights to High-Value Bone Regeneration Tech
|
20 Oct 2025 8:56AM |
$1.310 |
$1.070 |
fallen by
18.32%
|
|
OCC - Price-sensitive ASX Announcement
Full Release
Key Points
- Orthocell increased its stake in Marine Biomedical to 12.0%
- Investment secures distribution rights for PearlBone™
- PearlBone™ is a next-generation bone substitute
- Product derived from sustainable pearl shells
- Enhances Orthocell’s regenerative medicine portfolio
- Strategic alignment with U.S. distribution networks
- Focus on orthopaedic, trauma, and reconstructive surgery markets
- Marine Biomedical aims for U.S. FDA approval by Q1 CY2026
- Investment aims to enhance patient outcomes and shareholder value
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Brainchip Holdings Ltd (BRN) ORDINARY FULLY PAID |
Information Technology |
$394 |
Investor Presentation
|
20 Oct 2025 8:56AM |
$0.210 |
$0.175 |
fallen by
16.67%
|
|
BRN - Price-sensitive ASX Announcement
Full Release
Key Points
- BrainChip Holdings Ltd. is a leader in Edge AI on-chip processing and learning.
- The company focuses on enabling on-device AI where size, weight, and power challenges prevail.
- Target markets include defense, medical, industrial, and consumer sectors.
- BrainChip's Akida technology provides ultra-low power event-based computing.
- The company has strong partnerships and collaborations with industry leaders and universities.
- BrainChip is expanding its product portfolio to include IP, chips, software tools, and cloud enablement.
- The Edge AI market is anticipated to grow significantly by 2030, with BrainChip positioned to capitalize on this growth.
- The company's Akida-based products target high-growth markets such as space, defense, wearables, and private voice assistance.
- BrainChip maintains a strong patent portfolio and employs a majority of engineers with advanced degrees.
- The company's strategy emphasizes solving customer problems through a combination of algorithms and efficient hardware execution.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Thorney Opportunities Ltd (TOP) ORDINARY FULLY PAID |
Financials |
$113 |
Update - Notification of buy-back - TOP
|
20 Oct 2025 8:55AM |
$0.685 |
$0.660 |
fallen by
3.65%
|
|
| Koonenberry gold Limited (KNB) ORDINARY FULLY PAID |
Materials |
$44 |
KNB triples the potential strike length of Enmore Gold
|
20 Oct 2025 8:55AM |
$0.052 |
$0.043 |
fallen by
17.31%
|
|
KNB - Price-sensitive ASX Announcement
Full Release
Key Points
- KNB triples potential strike length of Enmore Gold.
- Koonenberry Gold completed acquisition of Enmore Gold and Lachlan Projects in NSW.
- KNB commenced drilling at Enmore Gold Project.
- Multiple zones of visible gold identified in initial drill holes.
- The Sunnyside gold system expanded to more than 230m strike.
- KNB returned notable gold intersections from drilling.
- Significant potential for gold and antimony targets at Enmore.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ventia Services Group Limited (VNT) ORDINARY FULLY PAID |
Industrials |
$4,908 |
Update - Notification of buy-back - VNT
|
20 Oct 2025 8:54AM |
$5.470 |
$5.930 |
risen by
8.41%
|
|
| Maronan Metals Limited (MMA) ORDINARY FULLY PAID |
Materials |
$112 |
Notice of Annual General Meeting/Proxy Form
|
20 Oct 2025 8:53AM |
$0.355 |
$0.445 |
risen by
25.35%
|
|
| Brainchip Holdings Ltd (BRN) ORDINARY FULLY PAID |
Information Technology |
$394 |
AKD1500 Tape-out for Volume Production
|
20 Oct 2025 8:52AM |
$0.210 |
$0.175 |
fallen by
16.67%
|
|
BRN - Price-sensitive ASX Announcement
Full Release
Key Points
- BrainChip commences AKD1500 tape-out for volume production.
- The initiative is driven by customer demand and market trends.
- Forecasts production parts available by late Q3 of 2026.
- Production and testing costs are approximately $2.3M USD.
- AKD1500 leverages low-power, energy-efficient Akida technology.
- Targets markets include military, aerospace, medical, and consumer wearables.
- Enhances BrainChip's role in delivering full-stack AI solutions.
- Expected benefits include reduced latency, cloud costs, and improved data security.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| American Rare Earths Limited (ARR) ORDINARY FULLY PAID |
Materials |
$209 |
Application for quotation of securities - ARR
|
20 Oct 2025 8:52AM |
$0.565 |
$0.365 |
fallen by
35.40%
|
|
Call 1300 880 160
Start a chat
Schedule a call
